Placental transfer of the HIV integrase inhibitor dolutegravir in anex vivohuman cotyledon perfusion model | Zendy

Stein Schalkwijk | Zendy; Rick Greupink | Zendy; Angela Colbers | Zendy; Alfons C. Wouterse | Zendy; Viviènne Verweij | Zendy; J. van Drongelen | Zendy; Marga Teulen | Zendy; Daphne van den Oetelaar | Zendy; David M. Burger | Zendy; Frans G. M. Rüssel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Placental transfer of the HIV integrase inhibitor dolutegravir in anex vivohuman cotyledon perfusion model

Author(s) -

Stein Schalkwijk,

Rick Greupink,

Angela Colbers,

Alfons C. Wouterse,

Viviènne Verweij,

J. van Drongelen,

Marga Teulen,

Daphne van den Oetelaar,

David M. Burger,

Frans G. M. Rüssel

Publication year - 2015

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkv358

Subject(s) - dolutegravir , ex vivo , fetal circulation , medicine , perfusion , fetus , pharmacology , placenta , in vivo , andrology , pregnancy , virology , human immunodeficiency virus (hiv) , viral load , biology , antiretroviral therapy , genetics , microbiology and biotechnology

Data on fetal exposure to antiretroviral agents during pregnancy are important to estimate their potential for prevention of mother-to-child transmission (PMTCT) and possible toxicity. For the recently developed HIV integrase inhibitor dolutegravir, clinical data on fetal disposition are not yet available. Dual perfusion of a single placental lobule (cotyledon) provides a useful ex vivo model to predict the in vivo maternal-to-fetal transfer of this drug. The aim of this study was to estimate the transfer of dolutegravir across the human term placenta, using a dual-perfusion cotyledon model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research